- call +1-201-465-4211
- email sales@mrinsights.biz
Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma.
Scope of the Report:
This report studies the Myasthenia Gravis Disease market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Myasthenia Gravis Disease market by product type and applications/end industries.
Myasthenia gravis is generally treated with medications known as acetylcholinesterase inhibitors such as neostigmineand pyridostigmine. Immunosuppressants, such as prednisone or azathioprine, may also be used. The surgical removal of the thymus gland may improve symptoms in certain cases. Plasmapheresis and high dose intravenous immunoglobulin may be used during sudden flares of the condition. If the breathing muscles become significantly weak, mechanical ventilation may be required.
The global Myasthenia Gravis Disease market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Myasthenia Gravis Disease.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Valeant Pharmaceuticals
Sun Pharmaceuticals Industries
Novartis Pharmaceuticals
Teva Pharmaceutical Industries
Cipla
Roche
Apotex Corporation
Pfizer
Bristol-Myers And Company
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Imaging
Blood Tests
Electrodiagnostic
Edrophonium Test
Pulmonary Function Test
Market Segment by Applications, can be divided into
Hospitals
Clinics
Academic Research Institutes
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Myasthenia Gravis Disease Market Overview
1.1 Product Overview and Scope of Myasthenia Gravis Disease
1.2 Classification of Myasthenia Gravis Disease by Types
1.2.1 Global Myasthenia Gravis Disease Revenue Comparison by Types (2017-2023)
1.2.2 Global Myasthenia Gravis Disease Revenue Market Share by Types in 2017
1.2.3 Imaging
1.2.4 Blood Tests
1.2.5 Electrodiagnostic
1.2.6 Edrophonium Test
1.2.7 Pulmonary Function Test
1.3 Global Myasthenia Gravis Disease Market by Application
1.3.1 Global Myasthenia Gravis Disease Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Academic Research Institutes
1.4 Global Myasthenia Gravis Disease Market by Regions
1.4.1 Global Myasthenia Gravis Disease Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Myasthenia Gravis Disease Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Myasthenia Gravis Disease Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Myasthenia Gravis Disease Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Myasthenia Gravis Disease Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Myasthenia Gravis Disease Status and Prospect (2013-2023)
1.5 Global Market Size of Myasthenia Gravis Disease (2013-2023)
2 Manufacturers Profiles
2.1 Valeant Pharmaceuticals
2.1.1 Business Overview
2.1.2 Myasthenia Gravis Disease Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Valeant Pharmaceuticals Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sun Pharmaceuticals Industries
2.2.1 Business Overview
2.2.2 Myasthenia Gravis Disease Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sun Pharmaceuticals Industries Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis Pharmaceuticals
2.3.1 Business Overview
2.3.2 Myasthenia Gravis Disease Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis Pharmaceuticals Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.4 Teva Pharmaceutical Industries
2.4.1 Business Overview
2.4.2 Myasthenia Gravis Disease Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceutical Industries Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.5 Cipla
2.5.1 Business Overview
2.5.2 Myasthenia Gravis Disease Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Cipla Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.6 Roche
2.6.1 Business Overview
2.6.2 Myasthenia Gravis Disease Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Roche Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.7 Apotex Corporation
2.7.1 Business Overview
2.7.2 Myasthenia Gravis Disease Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Apotex Corporation Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.8 Pfizer
2.8.1 Business Overview
2.8.2 Myasthenia Gravis Disease Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Pfizer Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
2.9 Bristol-Myers And Company
2.9.1 Business Overview
2.9.2 Myasthenia Gravis Disease Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Bristol-Myers And Company Myasthenia Gravis Disease Revenue, Gross Margin and Market Share (2016-2017)
3 Global Myasthenia Gravis Disease Market Competition, by Players
3.1 Global Myasthenia Gravis Disease Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Myasthenia Gravis Disease Players Market Share
3.2.2 Top 10 Myasthenia Gravis Disease Players Market Share
3.3 Market Competition Trend
4 Global Myasthenia Gravis Disease Market Size by Regions
4.1 Global Myasthenia Gravis Disease Revenue and Market Share by Regions
4.2 North America Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
4.3 Europe Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
4.5 South America Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
5 North America Myasthenia Gravis Disease Revenue by Countries
5.1 North America Myasthenia Gravis Disease Revenue by Countries (2013-2018)
5.2 USA Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
5.3 Canada Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
5.4 Mexico Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
6 Europe Myasthenia Gravis Disease Revenue by Countries
6.1 Europe Myasthenia Gravis Disease Revenue by Countries (2013-2018)
6.2 Germany Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
6.3 UK Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
6.4 France Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
6.5 Russia Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
6.6 Italy Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Myasthenia Gravis Disease Revenue by Countries
7.1 Asia-Pacific Myasthenia Gravis Disease Revenue by Countries (2013-2018)
7.2 China Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
7.3 Japan Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
7.4 Korea Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
7.5 India Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
8 South America Myasthenia Gravis Disease Revenue by Countries
8.1 South America Myasthenia Gravis Disease Revenue by Countries (2013-2018)
8.2 Brazil Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
8.3 Argentina Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
8.4 Colombia Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Myasthenia Gravis Disease by Countries
9.1 Middle East and Africa Myasthenia Gravis Disease Revenue by Countries (2013-2018)
9.2 Saudi Arabia Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
9.3 UAE Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
9.4 Egypt Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
9.5 Nigeria Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
9.6 South Africa Myasthenia Gravis Disease Revenue and Growth Rate (2013-2018)
10 Global Myasthenia Gravis Disease Market Segment by Type
10.1 Global Myasthenia Gravis Disease Revenue and Market Share by Type (2013-2018)
10.2 Global Myasthenia Gravis Disease Market Forecast by Type (2018-2023)
10.3 Imaging Revenue Growth Rate (2013-2023)
10.4 Blood Tests Revenue Growth Rate (2013-2023)
10.5 Electrodiagnostic Revenue Growth Rate (2013-2023)
10.6 Edrophonium Test Revenue Growth Rate (2013-2023)
10.7 Pulmonary Function Test Revenue Growth Rate (2013-2023)
11 Global Myasthenia Gravis Disease Market Segment by Application
11.1 Global Myasthenia Gravis Disease Revenue Market Share by Application (2013-2018)
11.2 Myasthenia Gravis Disease Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Academic Research Institutes Revenue Growth (2013-2018)
12 Global Myasthenia Gravis Disease Market Size Forecast (2018-2023)
12.1 Global Myasthenia Gravis Disease Market Size Forecast (2018-2023)
12.2 Global Myasthenia Gravis Disease Market Forecast by Regions (2018-2023)
12.3 North America Myasthenia Gravis Disease Revenue Market Forecast (2018-2023)
12.4 Europe Myasthenia Gravis Disease Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Myasthenia Gravis Disease Revenue Market Forecast (2018-2023)
12.6 South America Myasthenia Gravis Disease Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Myasthenia Gravis Disease Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Myasthenia Gravis Disease Picture
Table Product Specifications of Myasthenia Gravis Disease
Table Global Myasthenia Gravis Disease and Revenue (Million USD) Market S
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
